Anabolic therapy with Equisetum arvense along with bone mineralising nutrients in ovariectomized rat model of osteoporosis.
OBJECTIVE
Equisetum arvense has been used to treat bone diseases. The traditional supplementation of calcium and Vitamin D for osteoporosis patients is insufficient considering the rise in patients every year. We have observed that extending the calcium and Vitamin D supplement with L-lysine, L-proline, L-arginine, and L-ascorbic acid (N) positively affects bone mineralization in ovariectomized rat. Here, we report a further extension of the above supplement with E. arvense.


MATERIALS AND METHODS
The changes in serum biomarkers, bone mineral content, and femur bone histology were studied and compared to the standard drug for osteoporosis, namely raloxifene (RAL).


RESULTS
We report a significant change in formation and resorption markers of bone as well as in cortical bone thickness and trabecular width in N and N + EA groups. The treatment N + EA also restored lipid profile near to normal level compared to ovariectomized group.


CONCLUSIONS
Treatment N + EA was found to be as effective as RAL in reversing the osteoporotic changes.
['Kotwal|Swati D|SD|', 'Badole|Smita R|SR|']
D045930:Anabolic Agents D000818:Animals D004195:Disease Models, Animal D019669:Embryophyta D005260:Female D051381:Rats D017208:Rats, Wistar
Equisetum arvense Bone mineralizing nutrients osteoporosis prevention